Cowen and Company’s Idexx Laboratories IDXX Stock Holding History

Cowen and Company’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-497	Closed	-$203K	–	631
2022 Q4	$203K	Sell	497 -830	-63%	-$322K	0.02%	177
2022 Q3	$432K	Buy	+1,327	New	+$487K	0.04%	132
2022 Q2	–	Sell	-1,363	Closed	-$746K	–	697
2022 Q1	$746K	Sell	1,363 -475	-26%	-$250K	0.07%	128
2021 Q4	$1.21M	Buy	+1,838	New	+$1.15M	0.11%	155

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cowen and Company's IDXX Position: Q1 2023 in Review

Cowen and Company sold out of Idexx Laboratories (IDXX) in Q1 2023, closing a stake of 497 shares — an estimated $203K sold.

Cowen and Company first reported a position in IDXX in Q4 2021 and held it in 4 quarters. The position peaked at $1.21M in Q4 2021. 1,055 funds tracked by Wall St. Rank hold IDXX as of Q1 2023.

Cowen and Company reported no remaining Idexx Laboratories position as of Q1 2023 after selling out during the quarter.
Cowen and Company sold 497 Idexx Laboratories shares in Q1 2023, an estimated $203K.
Cowen and Company first reported a position in Idexx Laboratories in Q4 2021 and held it in 4 quarters.
Cowen and Company's Idexx Laboratories position peaked at $1.21M in Q4 2021.
1,055 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2023.

Based on Cowen and Company's 13F filing for Q1 2023, filed 9 May 2023.